Navigation Links
Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/17/2011

otection and Affordable Care Act of 2010 ("PPACA"). The increase for the comparable annual period was primarily due to more revenue recognized from our contract with the NIAID during the first and second quarters of 2010 as well as the PPACA grant.

Operating Expenses Research and development expenses for the quarter and year ended December 31, 2010, were $4.5 million and $13.3 million, compared to $3.9 million and $9.4 million for the quarter and year ended December 31, 2009. The increases in the respective periods was primarily due to higher costs related to work performed for the NIAID contract as well as higher other outside services and contract labor expenses related to research and development projects. The increase was partially offset by a decrease in research and development expenses incurred by Inovio AS and Inovio Tec, as these entities ceased operations in 2009, as well as lower stock based compensation expense.

General and administrative expenses, which include business development expenses and amortization of intangible assets, for the quarter and year ended December 31, 2010, were $3.1 million and $12.1 million, compared to $2.6 million and $13.7 million for the quarter and year ended December 31, 2009. The increase for the three-month period was primarily due to a reversal of a deferred tax liability in the fourth quarter of 2009, which did not occur in 2010. The decrease for the annual period was primarily due to lower legal and related fees. These decreases were partially offset by an increase in recurring operating expenses, including the amortization of intangible assets acquired in the 2009 merger, due to a full year operating as a combined company in 2010.

Net Loss Attributable to Common Stockholders The $6.8 million decrease in net loss attributable to common stockholders for the year ended December 31, 2010, compared with the year ended 2009, resulted primarily from a decrease in the loss related to the change in fa
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
2. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
3. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
4. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
6. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
7. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
8. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
9. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
10. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
11. Akrimax Pharmaceuticals, LLC, Introduces NitroMist® (Nitroglycerin Lingual Aerosol) 400mcg/Spray
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Ill. and LONDON, Sept. 23 Following today’s announcements ... the European Medicines Agency (EMA) for rosiglitazone in the ... Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s commitment ... and to the millions of people living with type ...
... Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two ... of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®,-- ... Performance in Key Safety and Efficacy... -- ABBOTT PARK, Ill., Sept. 23 ... ...
Cached Medicine Technology:Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 2Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 3Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 5Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 6Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 7Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 8Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 9
(Date:7/28/2014)... divide unless there is enough oxygen present to support ... types circumvent this rule. Researchers at The Johns Hopkins ... cells, warning signals, enabling cancers to continue to divide ... the researchers found that lysosomes the cell,s protein ... also uncovered new evidence that certain drugs can halt ...
(Date:7/28/2014)... Parker Waichman LLP, a personal injury law firm ... heroes of 9/11 are never forgotten, comments that the September ... According to a VCF message dated July 3, ... or before October 12, 2012 must file a Registration Form ... who were allegedly injured by the toxic dust cloud that ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
(Date:7/28/2014)... Utah (PRWEB) July 28, 2014 Bariatric ... and drinks, announced that it will be introducing three ... of products this summer. The additional flavors include: , ... pure taste-free protein , Inspire Pomegranate Razz Berry -­ ... flavor of soft-serve vanilla cone , Bariatric Eating's ...
(Date:7/28/2014)... one of two dopamine-producing regions in the brain was ... isoflurane or propofol. In the August issue of ... report that rats anesthetized with continuous doses of either ... up in response to electrical stimulation delivered to the ... major dopamine-releasing area, the substantia nigra, did not induce ...
Breaking Medicine News(10 mins):Health News:Cell's recycling center implicated in division decisions 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4Health News:Bariatric Eating Announces Three New Protein Shake Flavors 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2
... By Steven Reinberg HealthDay Reporter , ... have prostate cancer that,s considered "intermediate risk," radiation plus ... a new study finds. This combination of treatments, ... prostate cancer or advanced disease, the researchers said. Men ...
... cardiologists are prone to misinterpreting electrocardiograms when using ... heart defects that could make exercising perilous, according ... School of Medicine and Lucile Packard Children,s Hospital. ... acumen of pediatric cardiologists from several health-care institutions ...
... HealthDay Reporter , WEDNESDAY, July 13 (HealthDay News) -- ... infection can significantly reduce the chance they will develop the ... is an extremely exciting finding for the field of HIV ... a University of Washington associate professor of global health. ...
... , WEDNESDAY, July 13 (HealthDay News) -- Rural workers are often ... loved one and their jobs, researchers report. According to ... University of New Hampshire, people who work in rural communities have ... lost pay or lost jobs and caring for themselves or a ...
... control, growing wildly and breaking all the rules of orderly ... is a balance between a cancer cell,s revved-up metabolism and ... depends on a hyperactive metabolism to fuel its rapid growth, ... reactive oxygen species (ROS) generated by such high metabolic demand. ...
... WEDNESDAY, July 13 (HealthDay News) -- Wearing flip-flops and baseball ... warns. "Most skin cancers occur on the parts of ... Rebecca Tung, director of the dermatology division at Loyola University ... release. "The problem with flip-flops and baseball caps is ...
Cached Medicine News:Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 2Health News:For Some Prostate Cancer Patients, Combo Treatment Improves Survival 3Health News:Pediatric cardiologists not always accurate in interpreting ECG results for young athletes 2Health News:Pediatric cardiologists not always accurate in interpreting ECG results for young athletes 3Health News:Drugs May Prevent HIV Spread Among Heterosexuals 2Health News:Drugs May Prevent HIV Spread Among Heterosexuals 3Health News:Rural Workers Often Lack Access to Sick Leave 2Health News:Taking out a cancer's co-dependency 2Health News:Taking out a cancer's co-dependency 3Health News:Flip-Flops, Baseball Caps May Raise Risk of Skin Cancer 2
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... super series slit ... Variable retinal scanning ... fundus diagnostic capability, ... potential field of ...
Volk indirect lenses. Wide field retinal diagnosis & treatment....
Medicine Products: